Delivery Order 75N93023D00016-75N93023F00003
Award Date 6/20/23
Potential Completion Date 6/19/30
Potential Value $3.5K
Federal Agency
Ultimate Awardee
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Frederick, MD 21702, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a delivery order award to Dynport Vaccine Company LLC (DVC), a subsidiary of General Dynamics Corp, under the $36 million Diagnostic Pre-Clinical Services Program IDIQ contract with the National Institute of Allergy and Infectious Diseases (NIAID). The task order is for a 7-year period of performance with a ceiling value of $3,500. It does not have a set-aside designation. Under this contract, DVC will provide a range of research, development, manufacturing, and testing services to...
- This is a delivery order under the "Therapeutics Against Infectious Diseases Phase 1" indefinite delivery, indefinite quantity (IDIQ) contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services. The order, valued at $5,167,891.00, funds a Phase 1 clinical trial unit for therapeutic candidates against infectious diseases. The prime contractor is Dynport Vaccine Company LLC, a subsidiary of General...
- This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp. The $129,318.29 contract is a cost-plus-fixed-fee delivery order under the "Therapeutics Against Infectious Diseases Phase 1" contract vehicle, which funds Phase 1 clinical trials for infectious disease therapeutics. Dynport will provide a range of services including preclinical development,...
- This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp. The $222,661 award is a delivery order under the Therapeutics Against Infectious Diseases Phase 1 IDIQ contract, which funds Phase 1 clinical trials for therapeutics against infectious diseases. The contract does not have a set-aside designation. This order is for Dynport to conduct Phase 1...
- This is a federal contract award with a potential value of $139,426.00, issued by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp. The contract is a Delivery Order under the "Therapeutics Against Infectious Diseases Phase 1" master IDIQ contract. The award is for a PHASE 1 CLINICAL TRIAL UNIT FOR THERAPEUTICS AGAINST...
- This is a $2,265,501.00 delivery order contract awarded to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation, by the National Institute of Allergy and Infectious Diseases (NIAID) under the Early Phase Clinical Trial Units (EPCTU) IDIQ contract vehicle. The contract is for cost plus fixed fee services to support early phase clinical trials, with a period of performance through July 15, 2025. The contract does not have a set-aside designation. Dynport Vaccine Company has...
- The National Institute of Allergy and Infectious Diseases issued a delivery order to Dynport Vaccine Company LLC on June 13, 2017, with a ceiling value of $3.86 million under the Therapeutics Against Infectious Diseases Phase 1 parent IDIQ for Phase 1 clinical trial services. The order funds Phase 1 clinical trial unit operations and study task area B activities supporting therapeutics development against infectious diseases. Place of performance is Durham, North Carolina. The award carries a...
- The National Institute of Allergy and Infectious Diseases awarded a definitive contract to Dynport Vaccine Company LLC for a Phase 1 Clinical Trial Unit for Therapeutics Against Infectious Diseases on May 30, 2008, with a ceiling value of $35.6 million and ultimate completion date of June 17, 2019. The contract employs cost plus fixed fee pricing. Work is performed in Frederick, MD. The solicitation describes establishment and operation of a clinical trial unit to support Phase 1 trials of...
- This delivery order, awarded on May 13, 2021, to Dynport Vaccine Company LLC (a General Dynamics subsidiary) by the National Institute of Allergy and Infectious Diseases (NIAID), provides $4.12 million under a cost-plus-fixed-fee structure to establish a Phase 1 Clinical Trial Unit for Therapeutics Against Infectious Diseases. The work is being performed in Frederick, Maryland, with an ultimate completion date of January 31, 2025. This delivery order is issued under the $346 million Early...
- <p>The National Institute of Allergy and Infectious Diseases issued a $50,000 delivery order to Deloitte Consulting LLP on December 13, 2016, for technical and administrative management services under the NIAID/DCR Technical and Administrative Management Services IDIQ.</p> <p>Place of performance is Arlington, VA. The order carried a firm fixed price and ultimate completion date of September 30, 2023. No set-aside was used.</p>